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Abstract:
Objective: Urothelial carcinoma (UC) of the kidney is a relatively rare but aggressive form of kidney cancer. Differential diagnosis of 
renal UC from renal cell carcinoma (RCC) can be difficult, but is critical for correct patient management. We aimed to use global gene 
expression profiling to identify genes specifically expressed in urothelial carcinoma (UC) of the kidney, with purpose of finding new 
biomarkers for differential diagnosis of UC of both upper and lower tract from normal tissues.
Materials and methods: Microarray gene expression profiling was performed on a variety of human kidney tumor samples,   including 
clear cell, papillary, chromophobe, oncocytoma, renal UC and normal kidney controls. Differentially expressed mRNAs in various 
  kidney tumor subtypes were thus identified. Protein expression in human UC tumor samples from both upper and lower urinary tract 
was evaluated by immunohistochemistry.
Results: FXYD3 (MAT-8) mRNA was specifically expressed in UC of the kidney and not in normal kidney tissue or in any RCC tumor 
subtypes. FXYD3 mRNA levels displayed equal or better prediction rate for the detection of renal UC than the mRNA levels of selected 
known UC markers as p63, vimentin, S100P, KRT20 and KRT7. Finally, immunohistochemical staining of clinical UC samples showed 
that FXYD3 protein is overexpressed in majority of UC of the upper genitourinary tract (encompassing the kidney, ∼90%) and in major-
ity of high grade bladder UC (∼84%, it’s ,40% in low grade tumors, P , 0.001) compared to normal kidney and bladder tissues.
Conclusion: FXYD3 may be a promising novel biomarker for the differential diagnosis of renal UC and a promising prognosis marker 
of UC from bladder. Because it was identified genome-widely, FXYD3 may have important biological ramifications for the genetic 
study of UC.
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Introduction
Urothelial carcinoma (UC) of the kidney, also known 
as transitional cell carcinoma, or urothelial cell car-
cinoma of upper urinary tract (UCC-UUT), is a rela-
tively uncommon form of kidney cancer arising from 
the urothelium lining of the renal pelvis and   calyces. 
UC  accounts  for  the  majority  of  bladder  cancer; 
however,  it  only  accounts  for  about  7%  of  renal 
neoplasms.1 UC of the renal pelvis is an aggressive 
tumor,  which  may  invade  the  renal  parenchyma, 
mimicking  primary  renal  cell    carcinoma  (RCC).2 
Similarly, advanced RCC can invade the pelvical-
ceal system. This can make differential diagnosis of 
RCCs and UC of the renal pelvis difficult.   Correct 
diagnosis  is  critical  for  determining  appropriate 
  surgery and   post-surgical treatments. For instance, 
UC of the upper urinary tract including renal   pelvis, 
calyces and ureters will require radical nephrectomy 
with  ureterectomy  and  bladder  cuff  resection. 
  However, RCC will require only partial or radical 
nephrectomy  without  extensive  ureter  resection. 
Therefore, identifying markers that can distinguish 
UC  from  RCC  is  of  great  importance.3  A  recent 
study shows that UC behaves identically in the upper 
and lower urinary tracts when stage and grade are 
  considered.4 We recently compared the gene expres-
sion profiles between upper and lower urinary tract 
UC, concluded that no significant profile differences 
exist between them.5 Therefore, any biomarkers for 
lower tract UC then will most likely be a biomarker 
for the upper tract UC.
Known diagnosis biomarkers for UCs are p63,6 
vimentin7 and S100P.1 Phe et al studied the   methylated 
genes as biomarkers in urothelial cell carcinomas of 
the urinary tract.8 p63 and S100P are UC specific 
  biomarkers that are expressed in UC of the kidney, 
but not in other renal tumors. Vimentin, on the other 
hand, is down regulated in UC but up regulated in 
most RCCs. Other studies have shown that   various 
cytokeratins can be used as effective biomarkers to 
distinguish between UC and RCC. Han and Duszak 
stated  that  coexpression  of  CK7  and  CK20  is  a 
  feature of UC that can be used to properly identify 
and   diagnose UC with extensive renal involvement.9 
However, as far as the authors know, identifying the 
differential biomarkers at genome-wide level has not 
been conducted in the literature.
We aimed to identify genes that are highly   specific 
in  one  type  or  subtype  of  kidney  cancer  and  thus 
can  serve  as  molecular  biomarkers  and  diagnostic 
tools. In this study, we examined the gene expres-
sion   profiles of 123 tumors of different subtypes and/
or  normal  kidney  tissue  samples  with  the  goal  of 
finding genes that are specific for UC of the kidney. 
The identified genes could have important biological 
ramifications, because of the ways it was identified 
genome-widely.
Materials and Methods
case selection for gene expression 
profiling study
We have previously established gene expression data 
from 45 clear cell, 15 papillary and l9   chromophobe 
RCCs; 14 UCs of the kidney; 15 oncocytoma and 
15  normal  kidney  tissue  specimens  as  described 
  previously.10 In total, 123 samples of different   kidney 
tumor  subtypes  and  normal  tissues  were  studied 
(Table  1).  These  specimens  were  obtained  from 
Spectrum Health Hospital of Grand Rapids, MI, the 
Cooperative Human Tissue Network (CHTN), Baylor 
University Medical Center at Dallas. TX, the Univer-
sity of California, Los Angeles (UCLA), the French 
Kidney Cancer Study Group, and at Johns Hopkins 
University in Baltimore. MD. Patients’ clinicopatho-
logical information for the 14 UCs from renal pelvis 
was listed in Table 2. Among them, 8 samples with 
missing Grade information were due to the fact that 
they came from the same cancer center (French) that 
we were unable to trace the sample information back 
at this time other than that the patients was diagnosed 
with  upper  tract  urothelial  carcinoma  at  treatment 
time. Apart from them, all the rest samples showed 
high to modest grade information.
examination of gene expression  
profiles in kidney tumors
All tissue was snap frozen in liquid nitrogen immedi-
ately following surgery and stored at -80 until extrac-
tion.  The  samples  were  homogenized  in    TRIZOL 
Reagent (Invitrogen, Carlsbad, CA). Ten   micrograms 
of total RNA was processed for the expression microar-
rays using the Affymetrix GeneChip   one-cycle target 
labeling kit (Affymetrix, Santa Clara, CA) accord-
ing  to  the  manufacturer’s  recommended  protocols. FXYD3: a promising biomarker for urothelial carcinoma
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The  resultant  biotinylated  cDNA  was  fragmented 
and then hybridized to the GeneChip human genome 
(54,675  probe  sets  in  total,  including  more  than 
35,000 human genes; Affymetrix). The arrays were 
washed, stained, and scanned using the Affymetrix 
Model 450 Fluidics Station and Affymetrix Model 
3000 scanner using the manufacturer’s recommended 
protocols.  The  scanned  data  was  obtained  by  the 
Affymetrix GeneChip Operating Software (GCOS) 
version 1.4.
evaluation and normalization  
of Affymetrix genechip data
Expression values were generated by using   Microarray 
Suite v5.0 software (Affymetrix). The probes were 
  filtered according to a new study.11 The   hybridizations 
were normalized by using the robust   multichip aver-
aging (rma) algorithm to obtain a summary expression 
level for each retained gene. This resulted in more 
than 17,000 gene expression levels per sample, each 
of which then had one numeric value to represent its 
relative expression intensity across the study cohort.
Immunohistochemical staining
Paraffin-embedded tissue sections of 99 UCs were 
collected for this study from three participating insti-
tutions  (Geisinger  Health  System, Tian-Jin  Cancer 
Hospital and Northwestern Memorial Hospital) with 
Institutional  Review  Board  approvals  from  each. 
These tissue samples represented a different cohort 
of samples from those used for the microarray study. 
Among them, 29 were from upper genitourinary tract 
Table 1. Summary of tumor samples analyzed in the gene expression experiments and Ihc study.
Tissue samples in gene expression experiments Tissue samples used in IHc study
subtypes Labels number of samples Organ Grade #samples
clear cell rcc cc 45 Bladder Low 33
chromophobe rcc ch 19 high 37
normal kidney nO 15 Total 70
Oncocytoma On 15 Upper gU Low 18
Papillary rcc PA 15 high 11
Urothelial carcinoma from kidney pelvis Uc 14 Total 29
Total 123 Total 99
Total in all studies: 222
Abbreviation: Upper gU, upper genitourinary tract.
Table 2. Patients’ clinicopathological information for the 14 Ucs in the microarray study.
pID Age Gender ethnicity Diagnosis Grade Tumor size(cm) Remarks
rUc007 rUc #
rUc011 rUc #
rUc014 rUc #
rUc009 rUc #
rUc012 rUc #
rUc016 rUc #
rUc010 rUc #
rUc013 rUc #
rUc023 rUc 2–3 4.5
rUc409 63 M W Papillary rUc 3 5.3 *
rUc226 76 F rUc high 3.5
rUc173 71 M W rUc high 3 *
rUc238 76 F rUc high 4.5
rUc214 52 M W rUc high 10
note: *Indicating the samples being misclassified consistently in our study; rUC, Urothelial carcinoma from renal pelvis; #Indicating the patient’s information 
was missing and cannot be traced back at this time.Zhang et al
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(GU) and 70 were from the bladder. We graded them 
using the 2004 WHO classification.12 18 (upper tract) 
and 33 (bladder) were diagnosed as low-grade UC 
and the remaining were classified as high-grade UC 
(Table 1). Immunohistochemistry was carried out on 
all the cases as previously described.10,13–15 Briefly, 
4 µm tissue sections were subjected to immunohis-
tochemistry using a rabbit polyclonal antibody spe-
cific  for  FXYD3  (Sigma Aldrich,  St.  Louis,  MO) 
at  1:50  dilution.  Endogenous  peroxidase  activity 
was  blocked  with  3%  hydrogen  peroxide. Antigen 
retrieval was carried out in citrate buffer (10 mM, 
pH = 9) for 20 minutes at 100 °C in a microwave 
oven. The primary antibody was applied for 1 hour 
at room temperature. A subsequent reaction was per-
formed with secondary mouse anti-rabbit antibody 
and biotin-free HRP enzyme labeled polymer of the 
EnVision-plus detection system (DAKO, Carpinteria, 
CA). A positive reaction was visualized with diamin-
obenzydine solution followed by counterstaining with 
  hematoxylin. The staining was interpreted as either 
positive or negative by urologic pathologists.
Statistical methods
Fold change of gene expression levels between two 
conditions was defined to be the ratio of the mean val-
ues of expression levels of one condition over the other, 
if the ratio was greater than 1; or the negative reverse 
of the ratio if otherwise. Fisher’s exact test was used 
to test the independence between variables represent-
ing the column and row of contingency tables. The 
two tailed studentized t-test was used to test the mean 
differences between two groups. Linear models for 
microarray data (limma) were used to find differen-
tial genes between the tumor types. If there were more 
than two tumor types to be compared, all pairs were 
included in the fitting model (specified in the contrast 
matrix for the model). The genes were sorted by their 
significance of F-test. Coefficient variation (CV) of a 
numeric vector was defined to be its standard devia-
tion (SD) divided by its mean. Supervised clustering 
was based on the limma selected genes. Unsupervised 
clustering was based on genes where the interquartile 
range (IQR) was greater than a specific value (0.5 in 
our case) and the CV was greater than a specific value 
(0.06 in our case). In all clustering studies, a hierarchi-
cal algorithm was used with the Euclidean distance for 
dissimilarities between the data samples. The slightly 
modified  “plot.phylo”  function  from  R  package 
  analysis of phylogenetics and   evolution (ape) was used 
to plot the clustering results. The numbers of genes 
used were arbitrarily chosen to be 500. The Pearson’s 
method  was  used  to  calculate  the  correlations. All 
data analyses were programmed using R platform of 
  version 2.6.2 or higher. A gene for a tumor sample was 
considered over- or under-expressed only if its expres-
sion intensity was at least three SDs away from the 
mean value of gene intensities from the   normal refer-
ences. A P-value of 0.05 or less was considered to be 
significant throughout the paper.
Results
Supervised and unsupervised clustering 
based on gene expression profiling
The filtered genes by IQR and CV were used to   perform 
unsupervised clustering (-7500 genes, Fig. 1A), and 
the top 500 genes identified by the limma method were 
used to do a supervised clustering study of the cohort 
(Fig. 1B). Both approaches showed that 12 out of 14 
UCs were tightly clustered together, distinct from the 
rest of the samples of other tumor subtypes or normal 
samples, indicating that UC of the kidney has a very 
unique gene expression profile from other renal cell 
neoplasm subtypes. They also indicated the potential 
usefulness of gene expression profiling in identify-
ing biomarkers that are specific to renal UC. The two 
misclassified samples were both identified to be white 
male with high grade tumors, but with one of them 
having papillary elements (rUC 173 and rUC 409, see 
Table 2). We do not yet know exactly why their gene 
expression profiles were so different from the rest of 
the UCs. These 14 UC samples have been intensively 
studied in5 with the two misclassified samples consis-
tently being misclassified in the study. The heatmap 
for the top 100 genes identified by limma method was 
shown in Figure 1C with FXYD3 being one of them. 
More details of its gene expression patterns will be 
discussed below.
Patterns of FXYD gene expressions  
in different renal tumors
Microarray  gene  expression  profiling  identified  the 
FXYD3 gene (also known as MAT-8) as one of the 
top three genes most differentially expressed between 
UC of the kidney and normal kidney tissue (average 
fold change = 10.5, P = 0.0006, Table 3), along other FXYD3: a promising biomarker for urothelial carcinoma
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Figure 1. Unsupervised A) and supervised B) clustering on selected genes. The supervised clustering was based on selected genes most differentiable 
between the tumor types, while the unsupervised clustering was based on the filtered genes with maximal values of IQR and CV values among the study 
cohort. Most of the samples were clustered together correctly. UC is shown to have a particularly unique gene expression profile. c) heatmap of the top 
differential genes between Uc samples and normal references. FXYD3 is one of the top 3 genes shown in the heatmap. The other two are S100P and 
TrIM29, also shown in the plot.
Abbreviations: no, normal; UC, urothelial; PA, papillary; ON, oncocytoma; CH, chromophobe; CC, clear cell RCC.
genes  with  similar  gene  expression  patterns  to  that 
of FXYD3; these genes include S100P and TRIM29, 
as were marked in Figure 1C. S100P in UC has been 
studied in.1 TRIM29 also known as ATDC gene, was 
studied in lung cancer in.16 Among all kidney tumor 
subtypes and normal kidneys, FXYD3 is expressed in 
UC only (see below). It is a member of the FXYD fam-
ily of proteins, which have been implicated in regula-
tion of the Na, K+ ATPase and are characterized by 
a conserved FXYD motif.17–19 Based upon FXYD3’s 
up regulated expression in renal UC and its possible 
roles in UC tumors, we carefully examined the gene 
  expression patterns of all FXYD gene members in dif-
ferent kidney tumors (Fig. 2). We found that FXYD3 
expression was highly specific to UC of the kidney; it 
was not expressed in all other types of renal tumors and 
normal renal tissues (Fig. 2C). This UC specificity was 
not seen for the other FXYD family members. Interest-
ingly, FXYD1 was specifically up regulated in clear cell 
renal cell carcinoma (Fig. 2A), while the other FXYD 
family members had variable gene expression patterns 
in the different kidney tumor subtypes (Fig. 2).
Table 3. Comparison of FXYD3 mRNA with other mRNAs identified as potential biomarkers for urothelial carcinoma of the 
renal pelvis.
Fold changes to normal Significant 
cases1
Uc vs. 
normal2
Significance3 Uc vs.  
Rcc2
Significance3
Mean Min Max
FXYD3 10.5 1.07 30.4 13/14 (93%) 0.00062 *** 0.00058 ***
p63 4.81 1.37 13.3 12/14 (86%) 0.0036 ** 0.0034 **
KrT20 37 -1.36 181 7/14 (50%) 0.046 * 0.046 *
KrT7 11.2 -4.92 28.4 10/14 (71%) 0.00088 *** 0.00048 ***
S100P 107 3.9 275 12/14 (85.7%) 0.0011 ** 0.0011 **
Vimentin -3.61 -10.2 2.07 0/14 (0%) 0.032 * ,0.0001 ***
notes: 1Significant cases were defined to be at least 3 SDs away from normal mean expressions; 2P-values were obtained using two tailed student t-test; 
3Significance codes: 0–0.001 = ***, 0.001–0.01 = **, 0.01–0.05 = *, 0.05–0.1 = ., 0.1–1 = “ ”. Zhang et al
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correlation between gene expression 
patterns of the FXYD family genes  
in renal tumors
FXYD1  and  FXYD6  displayed  a  positive  correla-
tion (r = 0.91, P = 0.015, Fig. 2H) while FXYD2 and 
FXYD5 displayed an inverse correlation (r = -0.866, 
P = 0.024, Fig. 2I) between the medians of gene expres-
sion levels among the studied RCC tumor types. No 
genes in the FXYD family were found to be signifi-
cantly correlated with FXYD3, indicating the unique 
role it plays in UC. The negative correlation between 
FXYD2 and FXYD5 could possibly reflect negative 
feedback regulation between these two genes. Further 
study will be needed in this regard.
comparison of FXYD3 with other genes 
as biomarkers of Uc
The high specificity of FXYD3 expression to renal 
UC, but not to normal kidney tissue or other kid-
ney tumor subtypes, suggests possible application of 
FXYD3 as a biomarker for the differential diagnosis of 
UC of the kidney from other forms of kidney cancer. 
To   investigate this possibility, we selected five other 
potential biomarkers for comparison at the mRNA 
level: p63, vimentin, KRT7, KRT20 and S100P. Apart 
from vimentin, which was down regulated in UC, the 
other genes were all up regulated in UC of the kidney 
and showed some degree of UC specificity (Fig. 3). 
However, we noted that these biomarkers displayed 
more variation in expression among the cohort of UC 
samples than did FXYD3. 93% of renal UC samples 
overexpressed FXYD3, while 86%, 50%, 71% and 
85.7% of samples overexpressed p63, KRT20, KRT7 
and S100P, respectively (Table 3, see section Statisti-
cal Methods for calculating over or under expressed). 
KRT7 was also less specific to UC, as it was over-
expressed in some papillary and chromophobe RCCs 
(Fig.  3D). We  also  note  that  p63  showed  a  much 
smaller  average  fold  change  in  mRNA  expression 
between UCs and normal tissue (4.81 for p63 vs. 10.5 
for FXYD3, Table 3. A formal student’s t-test for the 
ability of these genes to differentiate between nor-
mal tissue and renal UC, and between renal UC and 
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Figure 3. Gene expression profiling of genes identified to be potential biomarkers. Left: individual gene expression intensity plot. Right: mean intensity + 
SD plot. A) FXYD3 over expression is highly specific to UC, with at least a 3-fold increase over normal kidney in 13 out of 14 (92.9%) cases tested. 
B) Overexpression of p63 was detected in 7 of 14 (50%) UC samples. Overexpression is specific to UC, but not as consistent as FXYD3 overexpression. 
c) Overexpression of keratin 20 (KRT20) in Uc. D) Overexpression of keratin 7 (KRT7) in Uc. e) Overexpression of S100P was detected in 12 of 14 
(85.7%) UC samples. Overexpression is highly specific to UC, comparable to FXYD3 overexpression. F) Vimentin was down regulated in the majority of 
Uc cases, whereas it was up regulated in most clear cell and papillary rcc cases. however, down-regulation was also observed in most chromophobe 
RCC and oncocytoma cases, limiting its use as a UC specific biomarker.
Abbreviations: cc, clear cell; PA, papillary; ON, oncocytoma; Ch, chromophobe; No, normal; UC, urothelial carcinoma.
other renal carcinomas showed that FXYD3 performs 
at least as well as the other genes (Table 3). In sum-
mary, FXYD3 appeared to be more specific for UC of 
the kidney than the other tested biomarkers.
FXYD3 immunohistochemistry in Uc 
from bladder and from kidney pelvis
Immunohistochemical  analysis  was  performed 
to evaluate the levels of FXYD3 in UC tissue sec-
tions from both the upper genitourinary tract and the 
bladder. The majority of UCs, regardless of origin, 
stained positive for FXYD3 (70/99, .70%). About 
90% of UCs from renal pelvis stained positive for 
FXYD3,  while  this  proportion  decreased  to  about 
63% of stained UCs from bladder. In contrast, normal 
  kidney and bladder stromal tissues showed no stain-
ing (Figs. 4 and 5; Table 4). The benign urothelium 
showed mild to moderate staining. When the samples 
were divided into either high or low grade groups, 
there was a significant correlation between staining 
patterns  (positive/negative)  and  histological  grade 
(high/low)  for  the  samples  from  bladder  UC  only 
(P , 0.0001, Table 4). Higher FXYD3 activities are 
strongly  associated  with  higher  tumor  grade,  sug-
gesting a role for FXYD3 in tumor development and 
progression of bladder UC (Fig. 5). We concluded 
from  this  study  that  FXYD3  could  play  different 
roles in UCs from kidney pelvis and from bladder. It 
can be used to be an effective gene marker to distin-
guish between UC of kidney and normal tissues from 
  kidney. It may have prognostic values in UC tumors 
from bladder.
Discussion
We  have  previously  demonstrated  a  difference  in 
gene expression profiles between renal pelvic UC and 
RCC.20 Here with more cases in our study, we report 
here that UC of the renal pelvis shows a very distinct 
genetic signature from that of other types of renal 
epithelial tumors. This difference can be exploited to 
identify biomarkers specific to the disease to aid in 
diagnosis and distinguish between RCC and UC of the Zhang et al
24  Biomarker Insights 2011:6
FXYD3 is a member of the FXYD family of ion 
transport  regulatory  proteins.  These  transmembrane 
proteins are characterized by a conserved FXYD motif 
and have been shown to associate with and modulate the 
function of Na,K ATPase. FXYD3 has also been sug-
gested to act as a chloride channel or chloride channel 
regulator.21 Interestingly, FXYD3 has been found to be 
overexpressed in primary human breast cancer tumors,21 
cell lines,22 androgen-dependent prostate cancer,23 and 
pancreatic  cancers.19  Furthermore,    siRNA-mediated 
knockdown of FXYD3 in separate experiments showed 
reduction  in  the  proliferative  activity  of  both  PC-3 
and LNCaP prostate cancer cells24 and T3M4 pancreatic 
cancer cells25 in vitro. These   findings suggest a poten-
tial role for FXYD3 in the development and progression 
of certain cancers. Our finding that FXYD3 is overex-
pressed in the majority of UCs of bladder and kidney is 
consistent with a role for this protein in cancer develop-
ment and is consistent to a recent study in,26 in which 
the authors studied gene expression patterns of a group 
of selected genes with FXYD3 included, on 86 upper 
tract UCs. They did not find prognostic significance 
in the study cohort.   Interestingly, we note that FXYD3 
protein expression is correlated with increased tumor 
grade in bladder UC, but not in UC of the renal pelvis/
calices. In view of the conclusion that gene expression 
profiles between the two locations are highly similar,5 
our study here points to a subtle molecular differences 
in UC of different   origins. The strong correlation of 
FXYD3   protein expression with high grade may sug-
gest a potential prognostic role for FXYD3 in bladder 
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Figure 4. FXYD3 immunohistostaining for Uc of the renal pelvis. A, c, 
e, G, and I: H and e staining; B, D, F, H and J: FXYD3 staining. A, B) 
Low grade Uc showing strong membranous and cytoplasmic staining. 
c, D) Area of high grade Uc component showing strong membranous 
  staining. e, F) Area of low grade Uc component showing weak cytoplas-
mic   staining. G, H) high grade Uc cells invading perinephric fat showing 
strong FXYD3 staining. I, J) normal appearing renal cortex showing no 
staining in kidney parenchyma including glomeruli and proximal tubules, 
while focal FXYD3 staining is occasionally seen in normal distal tubules.
A B
C D
Figure 5. FXYD3 immunohisto staining for Uc from bladder in A) low 
grade and c) high grade bladder Uc in comparison with paired benign 
urothelium B) and D).
kidney. Using this approach, we identified the FXYD3 
gene as a marker that is specifically overexpressed at 
both the mRNA and protein levels in renal UC com-
pared to normal kidney tissue. Moreover, compari-
son of FXYD3 with other known renal UC markers 
showed that FXYD3 mRNA   levels displayed equal or 
better sensitivity and specificity for the detection of 
renal UC than did the mRNA levels of such known UC 
markers as p63, vimentin, KRT20 KRT7 and S100P. 
As a comparison study, we found that FXYD3 may 
serve as a prognostic marker for UC from bladder. 
This suggests different roles that FXYD3 plays in 
UCs from the two locations.FXYD3: a promising biomarker for urothelial carcinoma
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UC, though further studies using patient survival data 
are required to establish this. The functional signifi-
cance of FXYD3 expression in UC will also require fur-
ther study.
conclusions
Our results indicate that FXYD3 is a promising new 
biomarker for UC, particularly useful for the differ-
ential diagnosis of UC of the upper urinary tract from 
renal cell carcinoma. Overexpression of FXYD3 in 
UC also suggests that this protein may have a pro-
moting role in the development and progression of 
UC in bladder.
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